EGFR and non-small cell lung carcinoma: Hsu et al. 29 reported a higher incidence of BM in EGFR mutation carriers than EGFR wild-type (39.2% vs. 28.2%, p=0.038) and significantly longer median survival (22.4 months vs. 7.9 months, p<0.001) in 534 patients with stage IV NSCLC.